Status:
COMPLETED
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Case Western Reserve University
Ministere de la Sante Publique et de la Population, Haiti
Conditions:
Lymphatic Filariases
Eligibility:
All Genders
5+ years
Brief Summary
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities. Parameters measured will include: circulating filarial antigenemi...
Detailed Description
Results from clinical trials in Papua New Guinea and Cote d'Ivoire have shown that a single dose of three drugs (ivermectin, diethylcarbamazine, and albendazole \[IDA\]) was superior to standard two d...
Eligibility Criteria
Inclusion
- Age ≥ 5 years (males and females)
- Able to provide informed consent, or parental/guardian consent for young children, and assent for older children
Exclusion
- Unable or unwilling to provide informed consent or (for minors) lacking parental/guardian consent to participate in the study
Key Trial Info
Start Date :
October 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2019
Estimated Enrollment :
20092 Patients enrolled
Trial Details
Trial ID
NCT03352206
Start Date
October 18 2017
End Date
November 1 2019
Last Update
December 31 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Ministry of Health and Medical Services
Suva, Fiji
2
Ministere de la Sante Publique et de la Population
Port-au-Prince, Haiti
3
Vector Control Research Centre
Puducherry, India, 605006
4
Universitas Indonesia
Jakarta, Indonesia